

Lead development of orally available drug for diabetic retinopathy targeting transglutaminase 2 to inhibit vascular leakage

KMEDIhub



OPHTHALMOLOGY

Hit

Product Type	Small Molecule
Indication	Diabetic Retinopathy
Target	Transglutaminase 2 (TGase 2)
MoA(Mechanism of Action)	Inhibition of VEGFR induced vascular leakage by TGase 2 inhibition
Competitiveness	Better patient compliance by oral administration, better efficacy in STZ-DR mice model (ivt) than Eylea and imatinib, better vision improvement and TI, wider market positioning throughout NPDR and PDR, applicable to other diabetic complications
Development Stage	Hit
Route of Administration	oral